Health Canada Approves Abilify®; First Atypical Antipsychotic Treatment for Adoles with Schiz
One-third of people living with schizophrenia experience a psychotic episode by age 19
By Guest Column —— Bio and Archives--December 16, 2011
Health and Medicine | Comments | Back To Full Article
MONTREAL, - Health Canada has approved Abilify® (aripiprazole) for the treatment of schizophrenia in adolescents age 15 to 17, making it the first atypical antipsychotic to be specifically approved for this use in this patient population. Abilify was first approved in 2009 for the treatment of schizophrenia and Bipolar I disorder in adults.
Read Full Article...
Welcome to CFP’s Comment Section!
The Comment section of online publications is the new front in the ongoing Cancel Culture Battle.
Big Tech and Big Media are gunning for the Conservative Voice—through their Comment Sections.
Canada Free Press wishes to stay in the fight, and we want our fans, followers, commenters there with us.
We ask only that commenters keep it civil, keep it clean.
Thank You for your patience and for staying aboard the CFP ‘Mother Ship’.
READ OUR Commenting Policy